Olvidé mi contraseña
Asóciese a SIIC en Internet para utilizar sin límites tanto siicsalud como la totalidad de los servicios bibliográficos de la institución.
SIIC selecciona textos completos de calidad y de reciente publicación en fuentes prestigiosas del mundo
indizadas por SIIC Data Bases, capturadas en las mismas colecciones o en diversas bases especializadas.
La creciente cantidad de artículos con Acceso Abierto (Open
Access) amplía la oferta de lectura pero a su vez también, entre
tanta abundancia, complica al lector en su encuentro con los estudios
fundamentales. Para facilitarlo, profesionales biomédicos de SIIC
consultan diariamente una profusa cantidad de documentos que nutrirán
Textos completos autorizados (TCA).
Las citas de la sección TCA enlazan de manera legal, autorizada y
gratuita con los textos completos (full text) publicados en
los sitios oficiales de sus respectivas fuentes.
SIIC creó, produjo y opera con exclusividad el software TCA para la
interpretación de los diversos campos documentales que integran la
estructura de un estudio: especialidad, modalidad del estudio,
fuente, fechas de publicación y selección, definición de la fuente,
limitaciones de consulta, resumen en castellano, etc.
Si bien la mayoría de los textos seleccionados corresponden a
artículos originales, revisiones y guías, los lectores también
encontrarán comentarios, entrevistas, notas periodísticas, cartas a
autores u otros textos precursores de debates o aclaratorios.
Sociedad Iberoamericana de Información Científica (SIIC) selects
complete quality-full texts which have been recently published in
renowned sources worldwide and are indexed by SIIC Data
Bases.
The increasing number of Open Access articles widens the reading offer
but, also, such myriad complicates the readers search of fundamental
articles. To facilitate this, SIIC biomedical professionals daily
consult a profuse amount of documents that will feed
Authorized Full Texts (TCA, Spanish acronym).
The citations of the AFT section link legally, authorized and free of
charge with the full texts published in the official web sites of
their corresponding sources.
SIIC created, produced and handles the AFT software that deciphers
the various documentary fields that form part of the structure of a
study: specialty, study style, source, publication and selection
dates, source definition, query limitations, summary in Spanish,
etc.
While most of the selected texts belong to original articles,
reviews, and guidelines, readers will also find commentaries,
interviews, journalistic reports, letters to authors or other texts
that may lead to discussions or clarifications.
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices
Fuente:Trials
Tipo de trabajo:Estudio aleatorizado y controlado
Extracto:
ISRCTN reference number: ISRCTN10324656. Registered on April 24 2019.
Cita:Trials 2024 Apr 16; 25 (1) : 265.
Autor/es:Patel, Vishal C (a) McPhail, Mark J (b)
institución:(a) Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK. vishal.patel@nhs.net. (b) Institute of Liver Studies, Faculty of Life Sciences and Medicine, School of Immunology and Microbial Sciences, King's College London, London, UK. vishal.patel@nhs.net.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Sex-related differences in outcome of thoracic aortic surgery.
Sex-related differences in outcome of thoracic aortic surgery.
Fuente:Journal of Cardiothoracic Surgery
Tipo de trabajo:Guía
Extracto:
The outcome
after TAA surgery was less favorable in women with significantly increased
overall mortality. It highlights the need to focus on implementing personalized
surgery strategies and gender-specific guidelines in treating female patients
following TAA surgery.
Claves:Gender, Mortality, Risk factors, Thoracic aortic aneurysms, Thoracic aortic surgery
institución:(a) Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. (b) Department of Cardiovascular Surgery, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200168, China.
Conflicto:On behalf of all authors, I declare that there is no conflict of interest to disclose.
Gut microbiota-host lipid crosstalk in Alzheimer's disease: implications for disease progression and therapeutics.
Gut microbiota-host lipid crosstalk in Alzheimer's disease: implications for disease progression and therapeutics.
Fuente:Molecular Neurodegeneration
Extracto:
This review highlights the current understanding
of how gut microbiota disrupts lipid metabolism and discusses the implications of
these discoveries in guiding strategies for the prevention or treatment of
Alzheimer's disease based on existing data.
institución:(a) Department of Rehabilitation, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. (b) Department of Rehabilitation, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Factors promoting and hindering resilience in youth with inflammatory bowel disease: A descriptive qualitative study.
Factors promoting and hindering resilience in youth with inflammatory bowel disease: A descriptive qualitative study.
Fuente:Nursing Open
Extracto:
Health care professionals need to develop greater awareness of
factors, stemming from both the individual and the outside world, that hinder or
promote resilience in order to aid young patients with IBD. Building targeted
nursing measures to excavate the internal positive quality of patients, provide
external support and promote the development of resilience.
institución:(a) Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China. (b) Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China.
Conflicto:All authors have no financial or other relationships to report.
A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.
A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.
Fuente:Gut Microbes
Extracto:
These results are both statistically significant and clinically meaningful,
representing, to the best of the authors' knowledge, the first positive results
observed for either a probiotic or postbiotic from the same strain, in this
particular population.
institución:(a) Clinical Development & Science Communications, Vedic Lifesciences Pvt Ltd, Mumbai, India. (b) Clinical Development & Science Communications, Vedic Lifesciences Pvt Ltd, Mumbai, India.
Conflicto:This study was funded by ADM. RD, MN and VV are all employees of ADM but were not involved in the study conduct, data management or statistical analysis.
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy.
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy.
Fuente:Cell Reports. Medicine
Extracto:
The application of microbiome-targeting approaches that
aim to improve immunotherapy efficacy (e.g., fecal microbiota transplantation,
probiotics, dietary intervention) is also elaborated, with further discussion on
current challenges and suggestions for future research.
institución:(a) Institute of Digestive Disease, Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Shatin, Hong Kong; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. (b) Institute of Digestive Disease, Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Shatin, Hong Kong.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Management of hepatorenal syndrome and associated outcomes
Management of hepatorenal syndrome and associated outcomes
Fuente:Bmj Open Gastroenterology
Tipo de trabajo:Revisión sistemática
Extracto:
This review showed that terlipressin has a
significantly higher reversal rate of HRS than the other treatments. Even the
results showed that terlipressin is more efficient than midodrine/octreotide and
norepinephrine as a previous medication, in reverse HRS, increasing patient
survival.
institución:(a) Shiraz University of Medical Sciences, shiraz, Iran (the Islamic Republic of). (b) Shiraz Nephro-Urology Research Center, Shiraz, Iran.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Quality of reporting inflammatory bowel disease randomised controlled trials
Quality of reporting inflammatory bowel disease randomised controlled trials
Fuente:Bmj Open Gastroenterology
Tipo de trabajo:Revisión sistemática
Extracto:
These findings are consistent with those of other
specialties in the literature. While this unclear risk of bias may represent poor
reporting of methods instead of poor methodological quality, it leaves readers
and future secondary researchers with significant questions regarding such key
issues.
institución:(a) School of Medicine, University of Central Lancashire, Preston, UK MGordon@uclan.ac.uk. (b) Blackpool Families Division, Blackpool Victoria Hospital, Blackpool, UK.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Scoping review of interventions to de-implement potentially harmful non-steroidal anti-inflammatory drugs (NSAIDs) in healthcare settings.
Scoping review of interventions to de-implement potentially harmful non-steroidal anti-inflammatory drugs (NSAIDs) in healthcare settings.
Fuente:Bmj Open
Tipo de trabajo:Revisión sistemática
Extracto:
Many varied interventions to de-implement
potentially harmful NSAIDs have been applied in healthcare settings worldwide.
Based on these findings and identified knowledge gaps, further efforts to
comprehensively evaluate the effectiveness of interventions and the combination
of intervention characteristics associated with effective de-implementation are
needed. In addition, future work should be guided by de-implementation theory,
focus on OTC NSAIDs and incorporate patient-focused strategies and outcomes,
including the evaluation of unintended consequences of the intervention.
Claves:Cardiovascular Disease, Chronic Pain, GERIATRIC MEDICINE, Health & safety, Primary Care, Quality in health care
Cita:BMJ Open 2024 Apr 17; 14 (4) : e078808.
Autor/es:Rockwell, Michelle S (a) Oyese, Emma G (b)
institución:(a) Family and Community Medicine, Carilion Clinic, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA msrock@vt.edu. (b) Family and Community Medicine, Carilion Clinic, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Randomised controlled, patient-blinded, multicentre, superiority trial to evaluate the efficacy of the line-attached sheath-type traction device for endoscopic submucosal dissection in patients with superficial gastric neoplasms.
Randomised controlled, patient-blinded, multicentre, superiority trial to evaluate the efficacy of the line-attached sheath-type traction device for endoscopic submucosal dissection in patients with superficial gastric neoplasms.
institución:(a) Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine School of Medicine, Kobe, Japan abe627@med.kobe-u.ac.jp. (b) Department of Gastroenterology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
institución:(a) Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. (b) Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Conflicto:Competing interests: TA reports personal grants from F. Hoffmann-La Roche, Biogen, AbbVie, Janssen, Celltrion, Galapagos, Immunodiagnostik and Takeda, outside the submitted work; personal fees for educational development/delivery from Pfizer, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, Takeda and F. Hoffman-La Roche; support for attending meetings from Celltrion, Tillotts and Pfizer. CAA reports...
grants from the Wellcome Sanger Institute Quinquennial Review 2021–2026, Crohn’s and Colitis Foundation (USA), the Medical Research Council, Open Targets UK and the Helmsley Charitable Trust; consulting fees from BridgeBio, Genomics and Brigham & Women’s Hospital Boston; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GlaxoSmithKline; support for attending meetings and/or travel membership from the Wellcome Sanger Institute Quinquennial Review 2021–2026; (Chair) of the Board of Trustees for the Sanger Prize; other interests as Director of Anderson Genomics Consultancy. MB reports partial personal salary funding from the Medical Research Council. ALH reports personal consulting fees from AbbVie, BMS, Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda, Roche and AbbVie; support for attending meetings and/or travel from BMS, Celltrion, Falk, Galapagos, Janssen, Pfizer, Takeda, Roche and AbbVie. PI reports personal grants from Celltrion, Galapagos and Pfizer, outside the submitted work; personal consulting fees from AbbVie, Takeda, BMS, Janssen, Arena, Pfizer, Galapagos, Lilly, Boehringer-Ingelheim and Celgene; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Takeda, Janssen, Lilly, BMS, Pfizer and Galapagos; support for attending meetings and/or travel from AbbVie and Tillotts. LJ-D reports grants from the Wellcome Trust, the Royal Society, the Kennedy Trust for Rheumatology Research, the Helmsley Charitable Trust and the Medical Research Council; grants from Novartis Pharmaceutical, outside the submitted work; consulting fees from Nightingale Health and Genomics. CK reports partial salary funding from the Medical Research Council. NAK reports grants from AbbVie, Biogen, Celltrion, Galapagos and Immunodiagnostik; consulting fees from AbbVie, Bristol-Meyers Squibb and Dr Falk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Dr Falk, Tillotts, Galapagos and Takeda; support for attending meetings and/or travel from Tillotts; participation (Chair) on the Board of the British Society of Gastroenterology IBD Clinical Research Group. CAL reports grants from and/or consultancy for Janssen, Takeda, AbbVie, AstraZeneca, Eli Lilly, Orion, Pfizer, Roche, Sanofi Aventis, UCB, Biogen, GSK, Bristol-Myers Squibb and Genentech; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring, Takeda, Janssen, Nordic Pharma and Dr Falk; participation (Secretary) on the British Society of Gastroenterology IBD Section; participation on the Steering Committee of IBD UK. CWL reports grants from UKRI Future Leaders Fellowship; personal consulting fees from AbbVie, Pfizer, Janssen, Takeda, Galapagos, Fresnius Kabi, Novartis/Sandoz, BMS and Celltrion; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Pfizer, Janssen, Takeda, Galapagos, Fresnius Kabi, Novartis/Sandoz, BMS, Ferring, Dr Falk and Celltrion. JOL reports grants from AbbVie, and Gilead; personal consulting fees from Allergan, AbbVie, Bristol-Myers Squibb, Celgene, Cornerstones US, Galapagos, Gilead, GSK, Lilly, MSD UK, Shire UK, Shire International, Ferring UK, Ferring International, Celltrion, Takeda, Pfizer and Janssen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Bristol-Myers Squibb, Cornerstones US, Galapagos, Ferring UK, Ferring International, Celltrion, Takeda, Pfizer and Janssen; support to attend meetings and/or travel from AbbVie and Janssen. RHM reports that she is an independent membership on the Trial Steering Committee for the National Institute for Health and Care Research funded ALLEGRO trial. JRM reports personal consulting fees from EnteroBiotix and Cultech; patent held (without financial gain) on Clostridium difficile therapy (WO2019197836A1), participation (Chair) on the IDMC Board. NMcG reports partial (10%) salary funding from the Medical Research Council. REM reports personal salary funding from the Wellcome Sanger Institute. JO reports stock held in Novartis. MP reports grants from Pfizer and Gilead; personal consulting fees from Galapagos; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen. NP reports grants from Bristol-Myers Squibb, Takeda and Pfizer; consulting fees from AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Celgene, Celltrion, Galapagos, GSK, Takeda and Vifor; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Bristol-Myers Squibb, Ferring, Galapagos, Janssen, Roche, Pfizer, Takeda and Tillotts; support for attending meetings and/or travel from AbbVie, Allergan, Celltrion, Janssen and Takeda; participation on a data safety monitoring board or advisory board for AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Celgene, Celltrion, Galapagos, GSK, Takeda and Vifor. TR reports personal grants from AbbVie; personal consulting fees from AbbVie, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Roche, Sandoz, Takeda, UCB and XAP therapeutics; participation on the board of UCB, membership (Chair) of the ECCO Guidelines Committee, membership of the UEG Scientific Committee. JS reports grants from Crohn’s and Colitis UK, the Helmsley Charitable Trust, ECCO, the European Commission, CCFA and Action Medical Research; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche; participation on a Data Safety Monitoring Board or Advisory Board for the MODULATE trial and the TRIBUTE trial; leadership or fiduciary role as the Director of the Royal College of Physicians IBD Registry, and Governing Body Fellow at Green Templeton College. AS reports personal consulting fees from GSK; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Falk, and AbbVie; payment of conference fees to attend the British Society of Gastroenterology Annual Conference 2022 from Celltrion; participation on a Data Safety Monitoring Board or Advisory Board for the IBD-RESPONSE study (unpaid), and AbbVie; participation on the British Society of Gastroenterology IBD Section Committee. CJS reports personal consultancy fees from Astarte Medical; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Nestle Nutrition Institute. JW reports grants from Intercept; consulting fees from Worg and UCB; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen; participation on a Data Safety Monitoring Board or Advisory Board for Roche. KW reports grants from the Helsmsley Charitable Trust, Crohn’s and Colitis UK, Almond Board of California, Danone, International Dried Fruit and Nut Council, Medical Research Council, National Institute for Health and care Research; royalty or license payments for Volatile organic compounds in the diagnosis and management of irritable bowel syndrome, and Wiley BDA Advances in Nutrition & Dietetics book series; personal consulting fees from Danone; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen; support for attending meetings and/or travel from Yakult; participation on a Data Safety Monitoring Board or Advisory Board for the MODULATE trial (unpaid).
Distinct learning, retention, and generalization patterns in de novo learning versus motor adaptation.
Distinct learning, retention, and generalization patterns in de novo learning versus motor adaptation.
Fuente:Scientific Reports
Extracto:
Our results extend insights for distinguishing motor skill acquisition from
adapting well-known movements.
Cita:Sci Rep 2024 Apr 17; 14 (1) : 8906.
Autor/es:Gastrock, Raphael Q (a) 't Hart, Bernard Marius (b)
institución:(a) Centre for Vision Research, York University, Toronto, ON, M3J 1P3, Canada. raphaelgastrock@gmail.com. (b) Department of Psychology, York University, Toronto, ON, M3J 1P3, Canada. raphaelgastrock@gmail.com.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Inflammation and cytomegalovirus viremia during pregnancy drive sex-differentiated differences in mortality and immune development in HIV-exposed infants.
Inflammation and cytomegalovirus viremia during pregnancy drive sex-differentiated differences in mortality and immune development in HIV-exposed infants.
Fuente:Nature Communications
Extracto:
ClinicalTrials.gov/NCT01824940.
Cita:Nat Commun 2024 Apr 17; 15 (1) : 2909.
Autor/es:Evans, Ceri (a) Mutasa, Kuda (b)
institución:(a) Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe. ceri.evans@qmul.ac.uk. (b) Blizard Institute, Queen Mary University of London, London, UK. ceri.evans@qmul.ac.uk.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Assessing causal relationships between gut microbiota and psoriasis: evidence from two sample Mendelian randomization analysis.
Assessing causal relationships between gut microbiota and psoriasis: evidence from two sample Mendelian randomization analysis.
Fuente:Scientific Reports
Extracto:
It
beckons further research to unravel the intricacies of how the gut's microbial
constituents might sway psoriasis's pathogenesis.
Claves:GWAS, Genetics, Gut microbiota, Mendelian randomization, Psoriasis
Cita:Sci Rep 2024 Apr 17; 14 (1) : 8831.
Autor/es:Li, Yuan (a) Chen, Gaihe (b)
institución:(a) Department of Dermatology, The Fifth People's Hospital of Hainan Province, Haikou, China. (b) Department of Dermatology, The Fifth People's Hospital of Hainan Province, Haikou, China.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Randomized feature selection based semi-supervised latent Dirichlet allocation for microbiome analysis.
Randomized feature selection based semi-supervised latent Dirichlet allocation for microbiome analysis.
Fuente:Scientific Reports
Extracto:
The RFSLDA framework is attractive because it
(i) enhances clustering accuracy by identifying key bacteria types as indicators
of health status, (ii) identifies key bacteria types within each group based on
estimates of the proportion of bacteria types within the groups, and (iii)
computes a measure of within-group similarity to identify highly similar subjects
in terms of their health status.
institución:(a) Department of Statistics, University of Connecticut, Storrs, CT, USA. namitha.pais@uconn.edu. (b) Department of Statistics, University of Connecticut, Storrs, CT, USA.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
Fuente:Bmc Cancer
Tipo de trabajo:Metanálisis
Extracto:
Patients with STK11-mutant NSCLC had low PD-L1 expression
and ORR to ICIs, and their PFS and OS were worse than patients with STK11(wt)
after comprehensive treatment. In the future, more reasonable systematic
treatments should be explored for this subgroup of patients with STK11-mutant
NSCLC.
institución:(a) Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China. (b) Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
Conflicto:The authors declare no potential conflicts of interest.
Muscle loss phenotype in COPD is associated with adverse outcomes in the UK Biobank.
Muscle loss phenotype in COPD is associated with adverse outcomes in the UK Biobank.
Fuente:Bmc Pulmonary Medicine
Extracto:
Evidence of MLP is
common in a large population-based cohort of COPD and is associated with higher
risk for all-cause and COPD-related mortality.
Claves:Cachexia, Chronic obstructive pulmonary disease, Epidemiology, Sarcopenia, Skeletal muscle loss
Cita:BMC Pulm Med 2024 Apr 17; 24 (1) : 186.
Autor/es:Attaway, Amy H (a) Lopez, Rocio (b)
institución:(a) Departments of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, USA. (b) Center for Populations Health Research, Cleveland Clinic, Cleveland, OH, USA.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Causal impact of gut microbiota and associated metabolites on pulmonary arterial hypertension: a bidirectional Mendelian randomization study.
Causal impact of gut microbiota and associated metabolites on pulmonary arterial hypertension: a bidirectional Mendelian randomization study.
Fuente:Bmc Pulmonary Medicine
Extracto:
Gut microbiota were discovered suggestive
evidence of the impacts of genetically predicted abundancy of certain microbial
genera on PAH. Results of our study point that the production of SCFAs or TMAO
does not mediate this association, which remains to be explained mechanistically.
institución:(a) Center for Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 Beilishi Rd, Xicheng District, Beijing, 10003, China. (b) Emergency and Critical Care Center, Fuwai Hospital, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
institución:(a) Department of Urology, Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China. (b) Department of Urology, Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Conflicto:Los autores declaran no tener conflictos de interés con la investigación
Alergia
Anestesiología
Bioquímica
Cardiología
Cirugía
Dermatología
Endocrinología y Metabolismo
Enfermería
Gastroenterología
Hematología
Infectología
Inmunología
Medicina Interna
Nefrología
Neumonología
Neurología
Nutrición
Obstetricia y Ginecología
Odontología
Oncología
Otorrinolaringología
Pediatría
Salud Mental
Salud Pública
Urología
Más Especialidades
